{
 "name": "思捷優達-KY",
 "slug": "tw-7829",
 "aliases": [
  "英屬開曼群島商思捷優達(股)公司",
  "Dasher-KY",
  "7829"
 ],
 "ticker": "7829",
 "industry": "生技醫療業",
 "website": "https://dasherneuroscience.com",
 "summary": "思捷優達-KY（7829）是興櫃的生技醫療類股公司，2019 年成立，2025 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "英屬開曼群島商思捷優達(股)公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "Dasher-KY",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2025-06-03",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2019-06-21",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "林東和",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "曾宇鳳",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 993881600,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "https://dasherneuroscience.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：YA-101",
   "value": "多重系統退化症（MSA）｜全球第二期試驗進行中且已停止招募｜美國、日本、台灣",
   "unit": "",
   "as_of": "2026-08-19",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06848231",
   "note": "NCT06848231；Last Update Posted 2026-08-19；ACTIVE_NOT_RECRUITING。"
  },
  {
   "claim": "催化劑：YA-101",
   "value": "第二期試驗頂線數據｜2027-Q1（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-07-29",
   "source": "https://dasherneuroscience.com/dasher-neuroscience-completes-patient-enrollment-in-phase-2-global-clinical-trial-of-lead-ai-drug-candidate-ya-101-for-multiple-system-atrophy-msa/",
   "note": "NCT06848231；官網頁面發布日2026-07-29，內文dateline為2026-07-28。數據讀出預估不同於登錄之主要完成日。"
  },
  {
   "claim": "催化劑：YA-101",
   "value": "第二期試驗預估主要完成日｜2027-06-30｜已公告",
   "unit": "",
   "as_of": "2026-08-19",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06848231",
   "note": "NCT06848231；Primary Completion ESTIMATED；較7月公司發布的Q1 2027頂線時程晚，但不同事件不可互相取代。"
  },
  {
   "claim": "催化劑：YA-101",
   "value": "第二期試驗預估試驗完成日｜2027-12-31｜已公告",
   "unit": "",
   "as_of": "2026-08-19",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06848231",
   "note": "NCT06848231；Study Completion ESTIMATED。"
  },
  {
   "claim": "管線：YA-102",
   "value": "巴金森氏症｜研發中（來源未揭露臨床期別）｜地區未揭露",
   "unit": "",
   "as_of": "2026-07-29",
   "source": "https://dasherneuroscience.com/dasher-neuroscience-completes-patient-enrollment-in-phase-2-global-clinical-trial-of-lead-ai-drug-candidate-ya-101-for-multiple-system-atrophy-msa/",
   "note": "公司公告About段落列YA-102 for Parkinson’s disease under development；不推定已進入人體試驗。"
  },
  {
   "claim": "管線：YA-201",
   "value": "阿茲海默症｜臨床前研發｜地區未揭露",
   "unit": "",
   "as_of": "2026-07-29",
   "source": "https://dasherneuroscience.com/dasher-neuroscience-completes-patient-enrollment-in-phase-2-global-clinical-trial-of-lead-ai-drug-candidate-ya-101-for-multiple-system-atrophy-msa/",
   "note": "公司公告About段落明列two preclinical pipeline candidates，包含YA-201 for Alzheimer’s disease。"
  },
  {
   "claim": "管線：YA-301",
   "value": "思覺失調症｜臨床前研發｜地區未揭露",
   "unit": "",
   "as_of": "2026-07-29",
   "source": "https://dasherneuroscience.com/dasher-neuroscience-completes-patient-enrollment-in-phase-2-global-clinical-trial-of-lead-ai-drug-candidate-ya-101-for-multiple-system-atrophy-msa/",
   "note": "公司公告About段落明列two preclinical pipeline candidates，包含YA-301 for schizophrenia。"
  }
 ],
 "provided_by": "public_sources",
 "verified_at": "2026-10-22",
 "url": "https://drugnews.com.tw/companies/tw-7829.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}